Chemistry:GYKI-32887

From HandWiki

GYKI-32887, also known as RGH-7825, is a dopamine agonist and antiparkinsonian agent of the ergoline family which was never marketed.[1][2][3][4] It has a lysergamide-like structure but is not technically a lysergamide itself.[1] Similarly to other D2-like receptor agonists, direct injection of small doses of GYK-32887 into the nucleus accumbens decreases locomotor activity in rodents.[3] This effect can be blocked by D2-like receptor antagonists like haloperidol, fluphenazine, and sulpiride.[3] GYKI-32887 was first described in the scientific literature by 1983.[2][3][4]

See also

References

  1. ↑ 1.0 1.1 Organic-chemical Drugs and Their Synonyms: An International Survey. Wiley-VCH. 2001. ISBN 978-3-527-30247-5. https://books.google.com/books?id=zmpqAAAAMAAJ&q=%2522GYKI-32887%2522. Retrieved 30 June 2025. 
  2. ↑ 2.0 2.1 "Psychopharmacological Effects of a New Dopaminergic Agonist Compound GYK-32887.". Acta Pharmaceutica Suecica: 190–194. 1983. https://scholar.google.com/scholar?cluster=4486869655604559584. 
  3. ↑ 3.0 3.1 3.2 3.3 "Non-opiate beta-endorphin fragments and dopamine--VI. Behavioural analysis of the interaction between gamma-type endorphins and dopaminergic systems in the nucleus accumbens of rats". Neuropharmacology 23 (5): 511–516. May 1984. doi:10.1016/0028-3908(84)90023-6. PMID 6204246. 
  4. ↑ 4.0 4.1 "RGH-7825". Drugs of the Future 10 (9): 753. 1985. doi:10.1358/dof.1985.010.09.71741. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/6836532. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:GYKI-32887&oldid=4175949"